Please login to the form below

Not currently logged in

AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn

The agreement will focus on drug discovery, development and commercialisation of neurological diseases


AbbVie and Sosei Heptares (Sosei) have announced plans to enter into a new drug discovery partnership as part of an option-to-license agreement, aiming to discover, develop and commercialise small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with neurological disease.

The companies will utilise Sosei’s StaR technology and structure-based drug design (SBDD) platform in conjunction with AbbVie’s expertise in neuroscience and disease areas.

This latest agreement is the second between the two companies and expands on the first multi-target discovery deal signed in June 2020, which focuses on autoimmune and inflammatory disease areas.

According to the conditions of the new agreement, Sosei will orchestrate and fund R&D activities through the finalisation of Investigational New Drug (IND)-enabling studies, while AbbVie has the exclusive option to license up to three programmes at this stage. AbbVie will assume responsibility for clinical, regulatory and commercial development thereafter.

Sosei is due to receive an upfront payment of $40m on signing and is eligible to receive up to $40m in near-term research milestone payments, anticipated over the next three years. Additionally, as a further potential option, the company will receive development and commercial milestones totalling up to $1.2bn, plus tiered royalties on sales worldwide.

Matt Barnes, head of UK research and development at Sosei, said: “We are delighted to enter this new multi-target discovery collaboration with AbbVie in the neuroscience area, a therapeutic area in which we share deep and complementary experience and expertise.

“We have established a highly productive working relationship with our counterparts at AbbVie over the past two years through our initial collaboration and are very pleased with how this is progressing. We believe this strong foundation will enable us to get off to a quick start as we tackle the novel and challenging neurology targets under this new agreement.”

Article by
Fleur Jeffries

8th August 2022

From: Research, Sales



Subscribe to our email news alerts

Featured jobs


Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....